Enteris touts early-stage oral peptide delivery for pain; Iran researchers develop material for targeted delivery;

> Enteris BioPharma reported successful results in a Phase I trial of its oral delivery method for Cara Therapeutics' CR845 peptide for acute and chronic pain. Release

> Researchers in Iran have developed hydrophobic polysaccharides for drug delivery. The material showed lower toxicity for healthy cells, and the researchers were able to target its paclitaxel load to release at the site of a tumor using biotin. More

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.